History

Background information

Leukaemia (chronic lymphocytic, first line) - rituximab: review decision - March 2014 information
Appendix B: GE decision paper - March 2014
Appendix B: GE decision paper - March 2014 (PDF 110 KB)

Published:

08 April 2014
Leukaemia (chronic lymphocytic, first line) - rituximab: Review Proposal - January 2014 information
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix A - provisional matrix of stakeholders
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix A - provisional matrix of stakeholders (PDF 101 KB)

Published:

20 January 2014
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 446 KB)

Published:

20 January 2014
Leukaemia (chronic lymphocytic, first line) - rituximab: review update - October 2012 information
Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - December 2010 information
NICE issues final guidance on the use of rituximab for first line chronic lymphocytic leukaemia (PDF 37 KB)

Published:

06 December 2013

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination information
Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination
Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination (PDF 138 KB)

Published:

15 June 2009
Response to consultee, commentator and public comments on the ACD and comments from website consultation
Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 120 KB)

Published:

15 June 2009
Consultee and commentator comments on the ACD
Chronic Lymphocytic Leukaemia Support Association
Chronic Lymphocytic Leukaemia Support Association (PDF 20 KB)

Published:

15 June 2009
Department of Health
Department of Health (PDF 13 KB)

Published:

15 June 2009
Leukaemia CARE
Leukaemia CARE (PDF 13 KB)

Published:

15 June 2009
Roche
Roche (PDF 100 KB)

Published:

15 June 2009
Royal College of Nursing
Royal College of Nursing (PDF 19 KB)

Published:

15 June 2009
Royal College of Pathologists
Royal College of Pathologists (PDF 8.3 KB)

Published:

15 June 2009
Comments from website consultation
Comments from website consultation (PDF 20 KB)

Published:

15 June 2009

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation
Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation document information
Leukaemia (chronic lymphocytic, first line) - rituximab: evaluation report
Pre-meeting briefing
Pre-meeting briefing (PDF 115 KB)

Published:

26 March 2009
Leukaemia (chronic lymphocytic, first line) - rituximab: evidence review group report
Leukaemia (chronic lymphocytic, first line) - rituximab: evidence review group report (PDF 3.61 MB)

Published:

26 March 2009
Non-manufacturer submissions
Chronic Lymphocytic Leukaemia Support
Chronic Lymphocytic Leukaemia Support (PDF 49 KB)

Published:

26 March 2009
Hampshire PCT
Hampshire PCT (PDF 24 KB)

Published:

26 March 2009
Royal College of Nursing
Royal College of Nursing (PDF 27 KB)

Published:

26 March 2009
Royal College of Physicians, Medical Oncology Joint Special Committee (on behalf of the NCRI/RCP/RCR/ACP/JCCO)
Royal College of Physicians, Medical Oncology Joint Special Committee (on behalf of the NCRI/RCP/RCR/ACP/JCCO) (PDF 89 KB)

Published:

26 March 2009
UK CLL Forum
UK CLL Forum (PDF 27 KB)

Published:

26 March 2009
UK CLL Forum, Royal College of Pathologists & British Society for Haematology
UK CLL Forum, Royal College of Pathologists & British Society for Haematology (PDF 40 KB)

Published:

26 March 2009
Expert written personal statements
Barnard
Barnard (PDF 97 KB)

Published:

26 March 2009
Milligan
Milligan (PDF 14 KB)

Published:

26 March 2009
Pettitt
Pettitt (PDF 19 KB)

Published:

26 March 2009
Williams Durkin
Williams Durkin (PDF 41 KB)

Published:

26 March 2009
Manufacturer submission
Roche submission
Roche submission (PDF 4.22 MB)

Published:

26 March 2009
Manufacturer response to clarification letter
Manufacturer response to clarification letter (PDF 309 KB)

Published:

26 March 2009
Manufacturer response to supplementary clarification letter
Manufacturer response to supplementary clarification letter (PDF 18 KB)

Published:

26 March 2009
NICE clarification letter
NICE clarification letter (PDF 35 KB)

Published:

26 March 2009
NICE supplementary clarification letter
NICE supplementary clarification letter (PDF 16 KB)

Published:

26 March 2009
Utility Measurement Study for Patients with Chronic Lymphocytic Leukaemia: Interim Report
Utility Measurement Study for Patients with Chronic Lymphocytic Leukaemia: Interim Report (PDF 165 KB)

Published:

26 March 2009

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (updated following CHMP positive opinion)

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (updated following CHMP positive opinion)
Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (PDF 27 KB)

Published:

24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope
Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (PDF 27 KB)

Published:

24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators
Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators (PDF 47 KB)

Published:

24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope
Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope (PDF 74 KB)

Published:

24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix
Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix (PDF 23 KB)

Published:

24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope
Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope (PDF 31 KB)

Published:

24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators
Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators (PDF 48 KB)

Published:

24 September 2008